622results about "Silicon compound active ingredients" patented technology

The invention discloses a general KRAS inhibitor, the structure of which is shown as a formula I. In the formula, the definition of each substituent group is shown in the description and claims. The general KRAS inhibitor has the advantages of easily available raw materials, simple synthesis, wide action range and strong effect, and can reduce or avoid the possibility of drug resistance generation. # imgabs0 #

The invention relates to the field of biological medicine, in particular to a compound and a preparation method and application thereof. Particularly, the invention relates to a compound shown in a formula (I) or pharmaceutically acceptable salt, stereoisomer, solvate, isotope labeled compound or polymorphic substance thereof, a preparation method thereof, a pharmaceutical composition containing the compound and application thereof, the compound can be used as a sodion channel inhibitor, has an analgesic effect, and can be used for preparing a sodion channel inhibitor. The compounds of the present application also have a variety of excellent properties. # imgabs0 #

The present invention relates to a nitrogen-containing tricyclic PRMT5 inhibitor, a method for producing the same, and a pharmaceutical use thereof. In particular, the present invention relates to a PRMT5 inhibitor having a structure represented by formula (I), a method for producing the same, a drug composition containing the same, and its use as a PRMT5 inhibitor and its use in the treatment and / or prevention of diseases mediated by PRMT5. Here, each substituent of formula (I) is the same as defined in the specification. 【Chemical 1】 TIFF2025516926000204.tif44144

The present disclosure is directed to DNA-PK inhibitors having the Formula (I), or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, methods of preparing the forgoing, and compositions thereof, as well as methods of use for the compounds of Formula (I), in combination with a DNA cutting agent.

The present disclosure is directed to DNA-PK inhibitors having the Formula (I), or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, methods of preparing the forgoing, and compositions thereof, as well as methods of use for the compounds of Formula (I), in combination with a DNA cutting agent.

The invention discloses a nitrogen-containing heterocyclic ring compound as well as a preparation method and application thereof, and particularly relates to a nitrogen-containing heterocyclic ring compound as shown in a general formula (I), or pharmaceutically acceptable salts thereof, or enantiomers, diastereoisomers, tautomers, torsion isomers, solvates, polymorphic substances or prodrugs thereof, and a preparation method and pharmaceutical application thereof. Wherein the definition of each group is described in the specification. # imgabs0 #

Disclosed herein are quaternary ammonium silane aqueous hydrogel formulations, including pharmaceutically acceptable aqueous hydrogel formulations, that provide high aqueous stability to an ammonium silane active moiety, as well as methods of use and manufacture.

The compound shown in formula I, its stereoisomers or pharmaceutically acceptable salts, or a pharmaceutical composition containing them, and their use in the manufacture of a therapeutic agent for treating related diseases as a PDE4B inhibitor, wherein each group shown in formula (I) is as defined in the specification. [Chemical formula 1] TIFF2025518257000169.tif37156

The invention relates to the technical field of medical chemistry, in particular to a bridge oxygen site regulatively modified rhodamine anti-cancer fluorescent compound as well as a preparation method and application thereof. The invention develops the rhodamine anti-cancer fluorescent compound of which the meso site is functionalized by tetraarylethene and the bridge oxygen site can be regulated and modified, the fluorescent compound has adjustable red light-near infrared fluorescence emission and excellent fluorescence quantum yield, and the quantum yield can be as high as 99%; the fluorescent compound specifically targets mitochondria, and mainly inhibits growth of tumor cells by inducing para-apoptosis; under irradiation of 655 nm near-infrared laser, ferroptosis is further triggered, efficient treatment of tumor cells is achieved through chemical-photodynamic synergistic effect, and a new treatment thought is provided for overcoming tumor drug resistance.

This invention is in the area of improved therapeutic combinations for and methods of treating selected retinoblastoma (Rb)-negative cancers and Rb-negative abnormal cellular proliferative disorders using particular topoisomerase inhibitors and specific cyclin-dependent kinase 4 / 6 (CDK4 / 6) inhibitors. In one aspect, the improved treatment of select Rb-negative cancers is disclosed using specific compounds disclosed herein in combination with a topoisomerase I inhibitor.

The invention discloses magnesium-containing mesoporous active bioglass with drug sustained release, immunoregulation and bone metabolism regulation effects and application thereof. The drug-loaded MBGN is prepared by doping Mg ions and loading drugs, and the drug-loaded MBGN has good biocompatibility and can be decomposed in an acid environment to achieve controllable slow release of the drugs; on the other hand, released ions such as Si, Ca and Mg have a certain immunoregulation function, polarization of macrophages from M1 type to M2 type is promoted, inflammatory response is reduced, differentiation and maturation of osteoclasts are inhibited, and meanwhile, the released ions and drugs carried in mesopores play a synergistic effect, so that a good treatment effect is achieved. The drug-loaded MBGN provided by the invention has various biological properties, can overcome the defects of low drug loading rate, insufficient anti-inflammatory effect and the like when the existing mesoporous bioactive glass material is applied clinically, and has a good application prospect.

The present invention aims to provide a novel compound having SF-1 antagonist activity, a multifunctional molecule containing a moiety corresponding to the compound, particularly an SF-1 Degrader. The present invention relates to a 3-phenylpropylamine derivative compound represented by formula (1) etc., and a multifunctional molecule containing a moiety corresponding to the compound represented by formula (1) etc. JPEG0007688242000190.jpg40145

A composition, usable for removing a biofilm and necrotic or infected tissues from skin lesions and lesions of the oral cavity, comprises methanesulfonic acid 99.0% and a proton acceptor. The proton acceptor is selected from the group consisting of: anhydrous sodium carbonate, 5-amino-2-mercaptobenzimidazole, ethylenediaminetetraacetic acid tetrasodium salt, sodium gluconate, sodium tartrate dihydrate, 2-mercapto-5-benzimidazole sodium sulfonate, dimethyl sulfoxide, polyethylene glycol 400, polyethylene glycol 600, silicon dioxide, tetraethoxysilane, and mixtures thereof. The aforesaid composition can be prepared in the form of a solution, gel or cream.

A method of selectively inhibiting pathogenic microbes includes: providing an antimicrobial compound that is functional having a structure of Formula 1, or derivative thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combination thereof; and contacting a microbe with the compound such that the microbe is selectively inhibited;

A method is provided for treating or preventing alcohol dependence and / or an alcohol associated disease or condition. Such a method includes administrating a pharmaceutical composition comprising an effective amount of a compound having formula (I):or a hydrates, a solvate, a pharmaceutically acceptable salt, a prodrug, or a complex thereof to a subject in need thereof. For example, (3S, 4R)-3-((R)-(1-hydroxy-ethyl)-4-((R)-[1-methyl-2-(4-methyl-piperazin-1-yl)-2-oxo-ethyl]-azetidin-2-one (MC-100093) is an exemplary compound. The composition can be used to prevent or treat alcohol dependence, attenuate alteration in glutamate transporters, reduce alcohol associated neuroinflammation, and treat or prevent alcohol associated fatty liver diseases.

Provided herein are compounds and pharma- ceutically acceptable salts thereof useful as KRAS G12D and / or KRAS G12C inhibitors, methods of making and using them (alone or in combination with additional agents), and pharmaceutical compositions thereof. The KRAS protein, Kirsten Rat Sarcoma 2 Viral Oncogene Homolog ("KRAS"), is a GTPase. KRAS gene mutations have been observed in several conditions, including, for example, pancreatic cancer, endometrial cancer, lung adenocarcinoma, colorectal cancer, rectal cancer, gallbladder cancer, thyroid cancer, cholangiocarcinoma, small cell lung cancer, and non-small cell lung cancer (NSCLC).

The present invention provides compounds (e.g., compounds of Formula (I)), as well as pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Implantable elements (e.g., devices and materials) containing them, and methods of their use, e.g., to treat or prevent a disease, disorder, or condition, are also provided. [Selection diagram] None

The invention relates to RIP1 inhibiting compounds and methods of making and using the same. In particular, disclosed herein are kinase inhibitory compounds, such as receptor interacting protein-1 (RIP1) kinase inhibitor compounds, and pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions and / or combinations may be used to treat or prevent kinase-related diseases or disorders, particularly RIP1-related diseases or disorders.

The present invention provides nitrogen-containing heterocyclic protein inhibitor compounds, their stereoisomers, tautomers or pharma- ceutically acceptable salts, and further provides the preparation of nitrogen-containing heterocyclic compounds and their uses, and medicaments prepared using such compounds have a wide range of uses in the treatment of diseases, including multiple types of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, lupus erythematosus, neurodermatitis, dermatitis, psoriasis, psoriatic arthritis, Crohn's disease, sicca syndrome and scleroderma.

The purpose of the present invention is to provide a novel compound having SF-1 antagonist activity, and a polyfunctional molecule comprising a moiety corresponding to this compound, particularly an SF-1 degrader. The present invention relates to a 3-phenylpropylamine derivative compound represented by formula (1), etc., and a polyfunctional molecule comprising a moiety corresponding to the compound represented by formula (1), etc.

The present invention relates to heterocyclic compounds, pharmaceutical compositions thereof, and methods which may be useful as inhibitors of IGF-1R for the treatment or prevention of thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy (TAO), or Graves' ophthalmopathy or orbitopathy (GO).

The present disclosure relates to near-infrared (NIR) photoimmunotherapy (PIT) for treating a subject with cancer, e.g., cancers including primary or primary tumors, metastatic tumor cells, and / or invasive tumor cells. The method includes administering to the subject a targeting molecule that binds to CD25 conjugated to a phthalocyanine dye, such as IR700, and administering an immune checkpoint inhibitor, such as an anti-PD-1 antibody, followed by irradiating the primary or primary tumor with a wavelength of light suitable for activating the phthalocyanine dye.

The present disclosure provides nitrogen-containing silicon ether ionizable lipid compounds and lipid nanoparticles including the ionizable lipid. The disclosure further relates to lipid nanoparticles including a provided ionizable lipid compound together with a phospholipid, e.g., a phospholipid that includes at least one unsaturated tail and a head group having a positively charged nitrogen. The provided materials are particularly beneficial in applications involving delivery of a nucleic acid. The disclosure also provides pharmaceutical compositions and methods including the provided ionizable lipids and / or lipid nanoparticles.

Compounds and compositions capable of modulating immune responses in patients, as well as implantable elements containing them, are provided. [Solution] For example, 4-((1-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methyl)thiomorpholine 1,1-dioxide, as well as pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives and compositions thereof, and implantable elements (e.g., devices and materials) containing these are provided.

The present invention relates to a stable silicic acid solution having a silicon content of 0.01-1.00% w / w. Silicic acid is stabilized by the combination of amino acid bisulfate 1AA, 1b, 1c, amino acid sodium and / or potassium 2aAA, 2bAA, 2c, 2d, 2e, 2f and sodium and / or potassium bisulfate (NaHSO4 and / or KHSO4) in a mixture of diol, 1, 2-propylene glycol (3) and / or polyethylene glycol (4) and purified water. The present invention discloses a method for preparing such a formulation. The composition is used as a food supplement, a functional food ingredient, a feed additive, a functional feed additive, a biostimulant for aquaculture, an active cosmetic ingredient, an active pharmaceutical ingredient, an agrochemical product and the like, and provides high bioavailability silicon (Si).

The present application provides a compound of formula (I) or a pharmaceutically acceptable salt thereof. A method for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof is provided. The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a CYP1A1 inhibitor is provided. The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or preventing tumors, bacterial infections, sepsis, inflammation, or organ damage is provided.

The present disclosure relates to tricyclic tetrahydroisoquinoline derivatives, their preparation methods, and their pharmaceutical applications. In particular, the present disclosure relates to tricyclic tetrahydroisoquinoline derivatives represented by general formula (I), their preparation methods, pharmaceutical compositions containing the derivatives, and their use as estrogen receptor modulators and in the preparation of drugs for treating estrogen receptor-mediated or dependent diseases or disorders. wherein, each substituent in general formula (I) is as defined in the specification. TIFF2023509944000122.tif5353